Sorry, you need to enable JavaScript to visit this website.

Greenstone LLC Announces Introduction of LATANOPROST Ophthalmic Solution — Its Latest Generic Pharmaceutical Product

PEAPACK, N.J., May, 2011 — Greenstone LLC, the generic pharmaceutical subsidiary of Pfizer Inc., is pleased to announce the introduction of LATANOPROST to its ever-expanding generic pharmaceutical product line.

LATANOPROST is the authorized generic of, and thereby fully substitutable for, Xalatan®. This new generic product from Greenstone is being offered in 125 mcg/2.5 mL Solution, available in single count and three count cartons.

LATANOPROST, which complements the consistently growing line of products from Greenstone, is supported by a company heritage of commitment to quality, reliable manufacturing, and customer-focused attention.

Xalatan® is a registered trademark of Pfizer Inc.